# Developmental Funds

> **NIH NIH P30** · NORTHWESTERN UNIVERSITY · 2021 · $615,923

## Abstract

ABSTRACT – DEVELOPMENTAL FUNDS
Developmental funds provide an essential source of support for the strategic initiatives of the Lurie Cancer Center
(LCC), consistent with its overall planning processes and priorities. In the current project period, we used CCSG
developmental funds in two major areas: recruitment of new investigators and development of one new shared
resource. CCSG funds were leveraged by additional institutional resources and philanthropy to support faculty
recruitment and retention, pilot projects, and equipment and technology upgrades of existing shared resource
facilities. The LCC Executive Committee determines the priorities for the allocation of Developmental Funds and
supplemental institutional support, with input from the Program Leaders and the External Advisory Board, to
ensure alignment with CCSG guidelines and the LCC strategic plan. Eight faculty received CCSG recruitment
support during the current cycle. In addition, during the current cycle, we used CCSG Developmental Funds to
support one new shared resource, the Proteomics Core Facility, which is presented as an established facility in
this application. Although CCSG funding was not used for pilot projects, the LCC invested substantially in
intramural awards. This value-added investment has stimulated and promoted innovative research efforts in
basic, clinical, translational and population sciences research, leading to new extramural grant funding, new
transdisciplinary collaborations and important cancer relevant publications.
Developmental Funds have leveraged additional institutional support and provided a superb return on
investment, with approximately $1 million CCSG funds allocated to new faculty recruits over this grant period,
generating a total of $33.3 million in grants and clinical trials; a 33-fold return on the investment (ROI). The $33.3
million includes $15.7 million in NIH funding, greater than 15 times the ROI of the CCSG funds invested. Given
the continued substantial growth of the LCC’s overall research enterprise, and the successful use of
Developmental Funds in the current project period, we request $400,000 per year to be used in two categories:
1. Recruitment of investigators in areas of strategic priority for the LCC, including cancer
immunology/immunotherapy, cancer epigenetics, cancer epidemiology and drug discovery and development. 2.
Development of a Metabolomics Core that will be of high value to LCC members.

## Key facts

- **NIH application ID:** 10228209
- **Project number:** 5P30CA060553-27
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** LEONIDAS C. PLATANIAS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $615,923
- **Award type:** 5
- **Project period:** 1997-08-15 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10228209

## Citation

> US National Institutes of Health, RePORTER application 10228209, Developmental Funds (5P30CA060553-27). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10228209. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*